Spitz I - Search Results

1

Effective long-term androgen suppression in men with prostate cancer using a hydrogel implant with the GnRH agonist histrelin.

Schlegel PN, Kuzma P, Frick J, Farkas A, Gomahr A, Spitz I, Chertin B, Mack D, Jungwirth A, King P, Nash H, Bardin CW, Moo-Young A. Schlegel PN, et al. Among authors: spitz i. Urology. 2001 Oct;58(4):578-82. doi: 10.1016/s0090-4295(01)01293-6. Urology. 2001. PMID: 11597543 Clinical Trial.

2

Reversibility of androgen deprivation therapy in patients with prostate cancer.

Fridmans A, Chertin B, Koulikov D, Lindenberg T, Gelber H, Leiter C, Farkas A, Spitz IM. Fridmans A, et al. J Urol. 2005 Mar;173(3):784-9. doi: 10.1097/01.ju.0000152330.63175.a5. J Urol. 2005. PMID: 15711270

3

An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.

Chertin B, Spitz IM, Lindenberg T, Algur N, Zer T, Kuzma P, Young AJ, Catane R, Farkas A. Chertin B, et al. Among authors: spitz im. J Urol. 2000 Mar;163(3):838-44. J Urol. 2000. PMID: 10687989 Clinical Trial.

4

Relationships between FSH, inhibin B, anti-Mullerian hormone, and testosterone during long-term treatment with the GnRH-agonist histrelin in patients with prostate cancer.

Eldar-Geva T, Liberty G, Chertin B, Fridmans A, Farkas A, Margalioth EJ, Spitz IM. Eldar-Geva T, et al. Among authors: spitz im. Eur J Endocrinol. 2010 Jan;162(1):177-81. doi: 10.1530/EJE-09-0366. Epub 2009 Oct 9. Eur J Endocrinol. 2010. PMID: 19820037

5

Long-acting gonadotropin-releasing hormone implant to maintain medical castration for two years in men with prostate cancer.

Spitz IM, Chertin B, Lindenberg T, Farkas A. Spitz IM, et al. N Engl J Med. 1999 May 6;340(18):1439. doi: 10.1056/NEJM199905063401814. N Engl J Med. 1999. PMID: 10328706 No abstract available.

6

Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists.

Spitz IM, Chertin B, Fridmans A, Farkas A, Belanger A, Hartman H, Labrie F. Spitz IM, et al. Prostate Cancer Prostatic Dis. 2009;12(1):100-3. doi: 10.1038/pcan.2008.15. Epub 2008 Jun 24. Prostate Cancer Prostatic Dis. 2009. PMID: 18574491

7

The histrelin implant: a novel treatment for central precocious puberty.

Hirsch HJ, Gillis D, Strich D, Chertin B, Farkas A, Lindenberg T, Gelber H, Spitz IM. Hirsch HJ, et al. Pediatrics. 2005 Dec;116(6):e798-802. doi: 10.1542/peds.2005-0538. Pediatrics. 2005. PMID: 16322137 Clinical Trial.

8

Is sildenafil citrate associated with an amelioration of the symptomatology of androgen decline in the aging male?

Koulikov D, Fridmans A, Chertin B, Shenfeld O, Farkas A, Spitz IM. Koulikov D, et al. J Urol. 2007 Jun;177(6):2267-71. doi: 10.1016/j.juro.2007.01.123. J Urol. 2007. PMID: 17509338 Clinical Trial.

9

A gonadotropin releasing hormone analogue prevents cyclical attacks of porphyria.

Anderson KE, Spitz IM, Bardin CW, Kappas A. Anderson KE, et al. Among authors: spitz im. Arch Intern Med. 1990 Jul;150(7):1469-74. Arch Intern Med. 1990. PMID: 2196028

10

Free alpha-subunit is the most sensitive marker of gonadotropin recovery after treatment of central precocious puberty with the histrelin implant.

Hirsch HJ, Lahlou N, Gillis D, Strich D, Rosenberg-Hagen B, Chertin B, Farkas A, Hartman H, Spitz IM. Hirsch HJ, et al. Among authors: spitz im. J Clin Endocrinol Metab. 2010 Jun;95(6):2841-4. doi: 10.1210/jc.2009-2078. Epub 2010 Mar 25. J Clin Endocrinol Metab. 2010. PMID: 20339028

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

177 results

Search Page

Filters